United Therapeutics Corporation (uthr)
UTHR — Company Overview
United Therapeutics Corporation (UTHR) trades on NMS as part of the Healthcare peer group (Drug Manufacturers - Specialty & Generic).
| Ticker | UTHR |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NMS |
| Market cap | $20.99B |
| Last price | $489.42 |
| Size category | Large Cap |
UTHR — Business Description
UTHR represents a Drug Manufacturers - Specialty & Generic business in the Healthcare segment. United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patien…
Official website: https://www.unither.com.
UTHR — Investment Thesis
At a high level, UTHR offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is contracting at roughly -1.9% year-over-year (public data).
- Trailing P/E of 17.38× sits in a moderate band relative to high-growth peers.
- Equity market capitalization is approximately $20.99B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
UTHR — Financial Health
Key financial health indicators for United Therapeutics Corporation are derived exclusively from public data — no proprietary estimates.
Profit margin of 41.6% indicates solid bottom-line conversion. Positive free cash flow of $557.14M supports balance-sheet flexibility.
| Trailing P/E | 17.38× |
| Forward P/E | 16.30× |
| Price / Sales | 6.65× |
| Price / Book | 3.26× |
| Gross margin | 86.1% |
| Operating margin | 42.2% |
| Profit margin | 41.6% |
| Return on equity | 19.3% |
| Free cash flow | $557.14M |
UTHR — Growth Outlook
Growth outlook for United Therapeutics Corporation (UTHR) depends on demand trends in Drug Manufacturers - Specialty & Generic and the company's ability to convert revenue into sustainable earnings.
- Revenue decline of -1.9% highlights near-term demand headwinds.
- Earnings growth of 13.4% year-over-year supports improving profitability.
- Price is 19.7% below the 52-week high.
- Shares trade 19.6% above the 52-week low — limited rebound so far.
UTHR — Competitive Position
United Therapeutics Corporation (UTHR) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - Specialty & Generic.
- Market capitalization of $20.99B places UTHR among large-cap peers.
- Gross margin near 86.1% may reflect pricing power or favorable mix.
UTHR — Strengths
Strengths for United Therapeutics Corporation (UTHR) inferred from public financial metrics:
- Earnings growth of 13.4% year-over-year.
- Return on equity near 19.3% — efficient use of shareholder capital.
- Gross margin of 86.1% supports competitive unit economics.
- Positive free cash flow ($557.14M).
- Large Cap scale ($20.99B) may provide distribution and funding advantages.
UTHR — Weaknesses
Weaknesses and pressure points for United Therapeutics Corporation (UTHR) based on available data:
- Revenue contraction of -1.9% year-over-year.
UTHR — Opportunities
- Trading 19.6% above the 52-week low — potential recovery if fundamentals stabilize.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
UTHR — Risks
- Negative revenue growth may signal share loss or cyclical pressure.
UTHR — Summary
United Therapeutics Corporation (UTHR) is a large-cap Healthcare company focused on Drug Manufacturers - Specialty & Generic, listed on NMS. Last price $489.42 with market cap $20.99B. Trailing P/E 17.38×. Revenue declined -1.9% year-over-year per public data. Notable strengths include earnings growth of 13.4% year-over-year. Key watch items include revenue contraction of -1.9% year-over-year. Premium Terminal tools for United Therapeutics Corporation add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open UTHR in Vest Terminal
Access live data, filings, ownership, and analysis for United Therapeutics Corporation.
United Therapeutics Corporation FAQ
What does United Therapeutics Corporation (UTHR) do?
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-fi…
What is UTHR's P/E ratio?
United Therapeutics Corporation has a trailing P/E of 17.38× based on publicly available market data.
Does UTHR pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is UTHR in?
United Therapeutics Corporation is classified in Healthcare (Drug Manufacturers - Specialty & Generic) on NMS.
What is UTHR's market capitalization?
Approximate market cap: $20.99B.
What are the main risks for UTHR?
Key risks include negative revenue growth, among factors on this page.
What are the strengths of UTHR?
Potential positives include earnings growth of 13.4% year-over-year, return on equity near 19.3% — efficient use of shareholder capital.
Where can I get analyst estimates for UTHR?
Public analyst price targets and consensus for United Therapeutics Corporation are on the free /stocks/uthr/estimates page. Deeper estimate history and models are available in Vest Terminal.